Login to Your Account



Gilead Invests $25M In Corus While Retaining Buyout Option

By Aaron Lorenzo


Friday, April 14, 2006
Gilead Sciences Inc. is putting $25 million into Corus Pharma Inc., and has an option to buy the rest of the respiratory disease-focused firm down the road. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription